The 2025 CDMO Landscape: Partnership Beyond Procurement
When a biotech misses its launch date, it’s rarely the science that fails – it’s the supply chain. In one 2024 case, a company developing a monoclonal antibody chose a CDMO solely based on cost per gram. Six months later, batch failures forced a rework that doubled expenses and delayed market entry by nearly a […]






